Abstract
Aerosol generation and characterization are critical components in the assessment of the inhalation hazards of engineered nanomaterials (NMs). An extensive review was conducted on aerosol generation and exposure apparatus as part of an international expert workshop convened to discuss the design of an in vitro testing strategy to assess pulmonary toxicity following exposure to aerosolized particles. More specifically, this workshop focused on the design of an in vitro method to predict the development of pulmonary fibrosis in humans following exposure to multi-walled carbon nanotubes (MWCNTs). Aerosol generators, for dry or liquid particle suspension aerosolization, and exposure chambers, including both commercially available systems and those developed by independent researchers, were evaluated. Additionally, characterization methods that can be used and the time points at which characterization can be conducted in order to interpret in vitro exposure results were assessed. Summarized below is the information presented and discussed regarding the relevance of various aerosol generation and characterization techniques specific to aerosolized MWCNTs exposed to cells cultured at the air-liquid interface (ALI). The generation of MWCNT aerosols relevant to human exposures and their characterization throughout exposure in an ALI system is critical for extrapolation of in vitro results to toxicological outcomes in humans.
Keywords: Aerosol engineering, Cell culture model, Exposure, Air-liquid interface, ALI, MWCNTs, Characterization
Background
Multi-walled carbon nanotubes (MWCNTs) are used in a number of consumer products, increasing the potential for inhalation exposure of these materials. Studies suggest that MWCNTs may pose a respiratory hazard to humans (e.g., the development of pulmonary fibrosis), depending on their physico-chemical characteristics [1–7]. Because of the possible link between inhalation exposure of MWCNTs and respiratory toxicity [8], there is interest in better understanding the mechanisms by which MWCNTs can induce inhalation toxicity. Regulatory agencies, such as the U.S. Environmental Protection Agency (EPA) Office of Pollution Prevention and Toxics (OPPT), recommend a 90-day rat inhalation test for MWCNTs if they present or may present an unreasonable risk to human health or the environment (as defined under Section 5 of TSCA) and are projected to be commercially produced.
Due to the substantive time, cost, and animal numbers required to conduct traditional in vivo inhalation toxicity tests there is much interest in in vitro methods to assess the toxicity of these materials. In vitro models have shown promise as human-relevant alternatives to animal testing, and have the capability to rapidly screen the vast number of substances that need to be assessed for toxicity. In vitro tests range from simple acellular or cellular high throughput tests to more complex tests, including three-dimensional (3-D) co-culture systems that better recapitulate the biology, physiology, and exposure dynamics that occur in human airways. An example of a simpler in vitro model for testing the lung effects of NMs could be submerged cultures of a single cell type, and an example of a more complex system could be a co-culture system of relevant cell types exposed to aerosolized NMs at the air-liquid interface (ALI). The two test types are complementary to one another in capability and relevance, offering high throughput (submerged cultures) and the potential for simulating relevant dosimetry with enhanced extrapolatability to the in vivo condition (3-D ALI cultures) when combined in a tiered testing strategy.
Inhalation toxicity was the subject of an international workshop held in Washington, D.C., USA on February 24–25, 2015. The workshop focused on the development of an in vitro test to predict the development of pulmonary fibrosis in cells exposed to aerosolized MWCNTs (Clippinger et al., this journal issue). Based on a literature review and workshop discussions, an in vitro system to assess pulmonary fibrosis following MWCNT exposure should consider aspects such as the mode of exposure (e.g., aerosol exposure of ALI cultures versus liquid media exposure of submerged cultures), relevant receptor (e.g., choice of cell types), concentration, and duration of exposure (e.g., relevance to real exposure scenarios). Characterization at multiple points throughout the MWCNT lifecycle is also important to understand the human relevance of the NM form present in the in vitro system. Presented below are the considerations related to conducting in vitro toxicological studies of aerosolized MWCNTs, including the apparatus and characterizations relevant to the development of an in vitro model to predict pulmonary fibrosis by monitoring pro-fibrotic signals in cells cultured at the ALI following exposure to MWCNTs.
Nanomaterial targets in the airways
When aerosolized, NMs can exhibit particle characteristics (e.g., size, density, and orientation) that determine their distribution and penetration into different areas of the respiratory system. The respiratory system can be divided into three main regions — nasopharyngeal, tracheobronchial, and alveolar — and is composed of more than 40 types of specialized cells. The alveoli are in a privileged location only accessible by particles with small aerodynamic diameter (usually ranging in size from 0.01–1 μm), are the primary site of gas exchange, and exhibit unique physiology not recapitulated in other parts of the airway [9]. The nasopharyngeal and tracheobronchial regions that constitute the conducting airways are covered by an extracellular fluid layer containing secreted high molecular weight glycoproteins (mucins) and watery secretions, which facilitate the removal of deposited particles (>10 μm) via the mucociliary escalator, active immunocyte surveillance, recruitment, and phagocytosis. Unlike the conducting airways, the alveoli only have a very thin (10–20 nm) epiphase consisting principally of surfactant, serum, and secreted proteins and lack mucociliary clearance allowing for longer retention of particles that reach the alveoli [10–12]. Additionally, the conducting airways limit systemic translocation of particles due to their thick epithelial barriers with deep, torsional channels, ability to slough damaged surface epithelial cells without loss of barrier integrity, and separation of blood from the airway by smooth muscle and connective tissue. Comparatively, alveoli are a very thin tissue barrier (~21 μm), exhibiting the shortest distance in the body between blood and the atmosphere [9, 13–17].
While significant advancements have been made to understand the role of alveoli in disease processes and outcome, much remains unknown because of the inherent limitations of the current test models. Therefore, there has been significant investment in the development of in vitro lung models that include relevant cell types cultured and exposed under physiologically relevant conditions. For instance, it has been suggested that the exposure of alveolar cells cultured at the ALI, in conjunction with other relevant cell types (such as macrophages and fibroblasts), is an ideal model to evaluate the inhalation toxicity of NMs [18]. Additionally, in order for such a model to accurately reflect human-relevant in vivo exposure, the mode of administration of NMs should be carefully considered. Thus, it is critical to evaluate the suitability of available cell culture systems for studying NMs as well as the techniques for aerosolizing and exposing NMs to cells cultured at the ALI.
Exposure methods
Cell cultures can be exposed to aerosolized materials by direct and indirect methods. Indirect exposure methods for aerosol studies typically involve collection of aerosols on sampling substrates (e.g., filter) or collection apparatus (e.g., wetted wall cyclones, wetted rotating vane impactors, or liquid impingers), followed by recovery of the collected aerosols and suspension of solid aerosols in culture medium before exposure of cells in a submerged culture [19, 20]. This indirect exposure technique has been used to investigate biological effects of a wide range of test materials from NMs to near-road ambient particles [21–23]. Although such techniques offer advantages for the testing of aerosols collected on-site, the intermediate steps, such as extraction of collected aerosols from the sample collection matrix and solubilization in exposure medium, could potentially alter the aerosol form and lead to false assessments.
Direct exposure methods are used for gas-phase exposure of test aerosols using several exposure techniques. Direct exposure methods enable administration of aerosolized materials directly to cultured cells under submerged conditions, intermittent exposure by a rocker platform, or continuous exposure at the ALI, among others [20, 24]. Direct continuous exposure at the ALI is more representative of human-relevant exposures than intermittent exposure and submerged systems, and it can be used to assess the potential hazards associated with aerosolized materials in a scalable, flexible, dosimetrically-relevant format that addresses the challenges put forth for modernizing toxicology testing [25].
In an ALI system, target cells are cultured on permeable and porous cell culture inserts (e.g., Transwell® inserts) and exposed to test atmospheres continuously on the apical surface, simulating the contact of pulmonary cells with inhaled air, while being nourished with medium from the basolateral surface. The ALI system provides a larger interface between airborne components and target cells as compared to the intermittent exposure or submerged exposure conditions. Additionally, ALI systems can limit the transformation of NM properties due to their interaction with the medium because the depth of the liquid on the surface of the ALI cell layer is significantly lower in comparison to submerged cultures. This is important because the transformations that NMs undergo in the exposure medium may influence the accuracy and reproducibility of the exposure. For example, one study showed aerosolized particles exposed at the ALI of a 3-D lung cell model to undergo far less agglomeration and thus less sedimentation compared to submerged cultures [26].
Development of ALI systems that recapitulate the human lung is ideal for testing MWCNTs, or other substances that may be inhaled, for their potential to cause fibrosis. While less complex systems, such as submerged cell cultures, are useful in understanding toxicity, ALI exposure of primary human cells cultured in a physiologically relevant 3-D configuration can aid in human risk assessment. Exposure of cells to aerosolized substances at the ALI requires an aerosol generator (to generate the test MWCNT atmosphere) and an exposure chamber (to deliver the aerosolized test MWCNT atmosphere to the cells at ALI). Figure 1 shows the basic configuration for an ALI exposure system. The aerosol generators and exposure chambers that are available to use with MWCNTs are discussed in the following sections.
Aerosol generation of MWCNTs
There are several methods commonly used for aerosol generation that differ in the basic principle used to generate the aerosols. Oberdörster et al. provides a comprehensive review of the generator and exposure systems that may be adapted to in vitro systems [27]. The physical characteristics of the material to be aerosolized, such as density, viscosity, state of matter, and target aerosol size, determine which generator should be used. MWCNTs can be delivered to cells either as a dry solid (dust) or liquid particle suspension aerosol. For liquid or biological materials, collision nebulizers, jet nebulizers, ultra-sonic atomization, or vibrating membrane generators are often used; whereas, the generation of aerosolized solid materials have typically employed the use of spray-drying, rotating scrapers, venturi-style powder dispersions, or fluidized powder bed methods [28–31]. When MWCNTs are delivered in a suspension (for instance, when using a nebulizer), it is important to understand if the suspension or carrier solvent contributes to the observed biological effect. Use of a dry aerosol generator (e.g., acoustic) allows for the evaluation of the relevance of the deposited form and concentration to the realistic exposure. When using nebulization, MWCNTs can be suspended in simulant lung surfactant; for dry aerosol generation methods, a cell line that secretes lung surfactant can be used to further simulate physiological conditions.
Descriptions of commonly used aerosol generation methods are shown in Table 1 as well as the type, size, concentration, and duration of aerosol generated using each. Each of the techniques has strengths and weaknesses depending on the nature of the material to be aerosolized, the particle size and concentration needed, and the duration of exposure. For instance, to assess the risk to humans, the ideal aerosol generator would be capable of generating MWCNTs in the human respirable size range (that is, particles that enter the lower respiratory tract and have a mass median aerodynamic diameter (MMAD) of between 1 and 3 microns) [32, 33]. Therefore, an aerosol generator should be carefully selected based on its suitability with the chosen MWCNT type and the requirements of the study design.
Table 1.
Type | Principle | Material type | Size range | Maintainable duration | Concentration range | Ref |
---|---|---|---|---|---|---|
Nebulizer | Droplets are formed with an atomizer or in a fountain formed by ultrasonic sound. Dried droplet residue forms the particles. | Liquids containing dissolved or suspended solids | 0.43–16.2 μm | Optimal for 6-h durations | 0.01–5 mg/m3 | [34] |
Electro spray Generator | High voltage is applied to a metal capillary end containing flowing liquid. Expelled charged droplets fragment when electrostatic forces exceed surface tension. Dried droplet residue forms the particles. | Liquids containing dissolved or suspended solids | 2- 100 nm | Optimal for 4 h | 5 ng/cm2/min for in vitro and 2 mg/m3 for in vivo | [35] |
Fluidized bed | Small beads are fluidized by air, and the turbulent motion and bead interaction disperses powder added to the bed. | Solid | 20–500 μm | Greater than 3 h | 0.5–40 mg/m3 | [31], [36] |
Acoustic | Includes an acoustic energy source and a diaphragm(s) that produce a pressure gradient. | Solid | Same as the original particle size | Greater than 30 h | 15 mg/m3 or more | [37] |
Brush feed | Composed of a screw feeder, rotating brush, and a cyclone designed to remove larger particles to aerosolize carbon fibers. | Solid | Same as the original particle size | In 6 h increments | 5 mg/m3 | [38] |
Dust feeder | The surface of a cake of compacted powder is scraped at a controlled rate, by mechanical scraping and blown by compressed air. | Solid | Same as the original particle size | >20 h | Concentration of the output aerosol can be controlled by adjusting the air-flow rate | [27, 39], [40] |
The table provides a brief description of aerosol generators that are applicable to MWCNTs, including the principle of aerosol generation, the type of material that can be aerosolized, the size and concentration of the aerosolized particle, and the duration of exposure to the aerosolized particles
Exposure chambers for MWCNT aerosolization
Chambers that can be used to expose cells cultured at the ALI to aerosolized materials have been described in the literature and include both commercially available systems and those developed by independent researchers [40, 41]. These chambers differ from each other in factors, such as cost, ease of availability and use, level of throughput, exposure time duration, and the number of examples of use in the published literature. Based on these factors, chambers from three organizations — VITROCELL® Systems, Cultex® Laboratories GmbH, and the University of Bern — were selected as most relevant for testing MWCNTs (Table 2). The chambers from VITROCELL® and Cultex® are commercially available, while the chamber from the University of Bern is produced in bulk (five at a time) by an independent researcher and is available on demand.
Table 2.
VITROCELL® 6/6, 12/12, OR 24/24 | VITROCELL® Cloud 6, 12, OR 24 | Cultex® RFS OR RFS COMPACT | University of Bern NACIVT | |
---|---|---|---|---|
What level of throughput can be achieved? | VITROCELL® 6/6 | VITROCELL® Cloud 6 | Cultex® RFS | NACIVT |
• 6-well inserts (can use adaptors to adapt to 12 or 24-well-sized) | • 6-well inserts | • 6, 12, or 24-well inserts | • 6-well inserts | |
• compartments for exposing 6 cell culture inserts | • compartments for exposing 6 cell culture inserts: 6 inserts at one exposure; no clean air control | • compartments for exposing 3 cell culture inserts - all exposed to the same substance | • compartments for exposing 24 cell culture inserts – allexposed to the same substance. | |
• allows for separate clean air exposure in one module: | • 1 well can be used for the (optional) microbalance. | • would have to purchase 2 modules for clean air control | • would have to purchase 2 modules for clean air control | |
o 3 replicates clean air control | ||||
o 3 replicates of one dose (or 2 replicates plus optional 1 well for microbalance) | ||||
VITROCELL® 12/12 | VITROCELL® Cloud 12 | Cultex® RFS Compact | ||
• 12-well inserts (can use adaptors to adapt to 24-well-sized) | • 12-well inserts | • 12 or 24-well inserts | ||
• compartments for exposing 12 cell culture inserts | • compartments for exposing 12 cell culture inserts | • compartments for exposing 6 cell culture inserts | ||
• allows for separate clean air exposure in one module: | • allows for separate clean air exposure in one module: | • allows for separate clean air exposure in one module | ||
o 3 replicates clean air control | o 3 replicates for clean air control | |||
o 3 dose dilutions with 3 replicates per dilution (or 2 replicates plus optional 1 well for microbalance) | o 9 inserts at one exposure (1 well can be used for the optional microbalance) | |||
VITROCELL® 24/24 | VITROCELL® Cloud 24 | |||
• 24-well inserts | • 24-well inserts | |||
• compartments for exposing 24 cell culture inserts | • compartments for exposing 24 cell culture inserts; 24 inserts at one exposure (1 well can be used for the optional microbalance) | |||
• allows for separate clean air exposure in one module: | • would have to purchase 2 modules for clean air control | |||
o 4 replicates clean air control | ||||
o 5 dose dilutions with 4 replicates per dilution (or 3 replicates plus optional 1 well for microbalance) | ||||
Commercially available? | Yes | Yes | Yes | No |
Deposited-dose determination | • The microbalance is capable of measuring the deposition in the module at a resolution of 10 ng/cm2. | 1 well can be used for the microbalance (optional). | Gravimetric methods, using the precision balance. | One of the wells is designed to carry a transmission electron microscope (TEM) grid to monitor exposure. Also has an electrometer. |
• For the 6/6 and 12/12, a built-in microbalance option is available. A microbalance sensor would occupy one compartment; therefore, the module should have at least 4 compartments in order to allow 3 replicates for exposure. | ||||
• For the 24/24, the purchase of a separate, standalone 12/1 CF module to use a microbalance would be needed. | ||||
Exposure Method | The VITROCELL® 6/6 is compatible with electrostatic deposition. | Not compatible with electrostatic deposition, but due to high deposition efficiency of NMs in the Cloud, electrostatic deposition is not needed (Cloud is equipped with a nebulizer that generates liquid aerosols). | Compatible with electrostatic deposition (both RFS and RFS compact). | Compatible with electrostatic deposition. |
The 12/12 and 24/24 are not, but in those cases, the VITROCELL® 6/6 modules can be used with adaptors for 12 or 24-well inserts. | ||||
Exposure time duration | Maximum 6 h possible | Approximately 3–4 min | Up to 1 h reported | Up to 2 h reported |
Ability to utilize multiple aerosol generating techniques? | May be used with a wide range of aerosol generators. | Compatible only with the aerosol generator, which is part of the delivery (vibrating mesh type for liquid aerosols). | May be used with a wide range of aerosol generators; One option is the Cultex® dust generator, which is a Mitchell or screw mill type. | May be used with a wide range of aerosol generators; Can be placed close to the workplace or aside a busy street. |
VITROCELL® Systems offer multiple chambers, including the ‘original’ (VITROCELL® 6, 12, and 24) and the Cloud (VITROCELL® Cloud 6, 12, and 24) set-ups. Cultex® Laboratories offer two chambers: the Radial Flow System (RFS) and the RFS Compact. The University of Bern manufactures an exposure module called the Nano Aerosol Chamber for In-Vitro Toxicity (NACIVT). Importantly, organizations frequently update existing modules or add new modules to their product line, and the information below is based on the status at the time of this publication. The chambers reviewed have several common features, including their compatibility with commercially available cell culture inserts and multiple aerosol generators, a mechanism to regulate temperature during exposure, and the ability to expose cells to aerosolized MWCNTs. However, there are differences that make each system unique, and these differences are detailed in the following sections.
Basic chamber configuration
Testing for the purpose of hazard assessment or identification requires specific attention to the number of replicates, appropriate controls, and quality assessment of the experiment. As the available aerosol exposure chambers exhibit limited end-user flexibility to modify the system configuration, the general need of the experiment must be assessed before deciding which system to use. For example, consideration should be given to whether the exposure chamber is: (1) capable of consistently delivering and depositing MWCNT aerosols at multiple dilutions; (2) compatible with different types of aerosol generators; (3) capable of determining the deposited dose; (4) readily cleaned; and (5) regularly available and consistently reproduced to facilitate interlaboratory transferability. Furthermore, the size of the cell culture inserts, the number of wells, and the number of different exposure concentrations that could simultaneously be tested per exposure system should be considered. To understand mechanisms of complex pathological outcomes, it is critical to focus on specific inter- and intra-cellular biomarkers (e.g., monitor multiple pro-fibrotic markers to understand the development of fibrosis), which will require a larger number of cells per exposure than are normally cultured in high throughput wells. Similarly, establishing a dose-response requires testing multiple concentrations of the test substance in one experiment, and therefore, it would be ideal to have a chamber with separate modules to accommodate different exposure concentrations (doses).
The ability to run a clean air exposure simultaneously with the MWCNT is ideal to associate the changes in biological responses to the test material. Some of the chambers (including VITROCELL® 6/6, 12/12, 24/24, Cloud 12, and Cultex® RFS Compact) provide the option of running clean air control experiments at the same time as the test material. For the chambers not capable of running simultaneous clean air control experiments (including VITROCELL® Cloud 6 and 24 Cultex® RFS, and NACIVT), either separate modules need to be purchased (one for the clean air control and one for the test substance), or if only one module is available, the clean air control experiment and test material experiment have to be run separately. This will double the time needed to conduct the study and will require that the module and auxiliary equipment are thoroughly cleaned between experiments to remove all traces of MWCNTs. Overall, the focus and goal of the study should be considered when choosing the exposure chamber. Although this review focuses on the three chambers (VITROCELL®, Cultex®, and NACIVT), the parameters described would also be relevant for the evaluation of other chambers.
Modularity
The exposure systems from the three manufacturers differ in their flexibility of peripherals and connections, with VITROCELL® Systems (with the exception of the VITROCELL® Cloud) being more modular in comparison to the Cultex® and NACIVT systems. Although modularity can provide the ability to fine tune the system and to expose different materials or different exposure concentrations (doses) at the same time, these modifications should only be made by someone with appropriate expertise and training since small variations in parameters (such as length of peripheral tubing) can impact the particle size and concentration of the MWCNT exposure atmosphere. The Cultex®, NACIVT, and the VITROCELL® Cloud systems, on the other hand, are built as one unit.
NM deposition
While all of the systems described above (except the VITROCELL® Cloud systems) allow for the use of different types of aerosol generators, there are considerable differences between the systems with regards to the duration for which the cells can be exposed to the aerosolized NMs (see Table 2). Exposure duration can significantly affect the amount of MWCNTs generated and deposited onto the cell layer and should therefore be carefully chosen. Large or dense particles in a moving airstream can be readily deposited through settling or impaction, as inertial and gravimetric forces are great enough to overcome thermodynamic and flow forces that would keep the particles suspended. Conversely, low-density particles, like MWCNTs, and those smaller than 100 nm deposit primarily via diffusion [42].
The issue of low deposition can be overcome by electrostatic deposition enhancement, which is a technique that uses charge to increase the efficiency of deposition by several fold (5–10 fold). For some materials, charge must first be added to the particles; however, this step is not necessary for aerosolized MWCNTs, which are extremely charged. The VITROCELL®, Cultex®, and NACIVT are adaptable to electrostatic deposition but dose enhancement is not available for VITROCELL® Cloud because it uses liquid aerosolization (i.e., nebulization) of MWCNTs, which yields high deposition efficiency. Although the physiological relevance of using electrostatic deposition is debatable, specified and reproducible concentrations of MWCNTs can be administered to cells via electrostatic deposition of aerosolized materials or nebulization of MWCNTs dispersed in a relevant medium (e.g., simulant lung surfactant).
Monitoring the deposited dose
The exposure chambers described above come with the option of a quartz crystal microbalance (QCM) that allows for a relatively quick and easy way to gauge deposition at a resolution of 10 ng/cm2. NACIVT also has the option of an internal aerosol electrometer to measure particle concentration in real time, so that the particle dose administered to the cells can be estimated. Alternative analytical methods to determine the deposited dose of MWCNTs for ALI cell cultures that can be used with all the available chamber systems involve techniques, such as laser spectrometry and electron microscopy (scanning electron microscopy (SEM) and transmission electron microscopy (TEM)) [43, 44].
Characterization of MWCNTs for assessing pulmonary toxicity using ALI systems
In addition to choosing the appropriate aerosol generation and exposure apparatus, it is critical to characterize MWCNTs to associate the observed endpoint to the causative NM property. Aerosol generation and exposure systems can be equipped with auxiliary equipment to characterize MWCNTs at various time points. There is consensus among researchers that characterization of the administered dose (used here to describe the exposure concentration times the volume of test atmosphere that flows through the ALI chamber) alone is not sufficient as NM properties may change following deposition and cellular uptake. It is therefore important to characterize and understand the MWCNT form throughout its lifecycle.
Ideally, physico-chemical properties of MWCNTs would be characterized in five separate stages (Fig. 2). The first stage occurs prior to aerosolization (pristine form/as supplied), the second is the MWCNT atmosphere present within the exposure chamber (administered dose), the third stage is the MWCNTs that settle on the cell surface (deposited dose), and the fourth stage is the MWCNTs taken up by the cells (cellular dose). In addition to the aforementioned stages, the fifth stage involves post-exposure evaluation of MWCNT transformations during the course of the assay, such as after each time point. The MWCNT characteristics that are relevant to some of the aforementioned stages include, but are not limited to: 1) agglomerate structure and (de) agglomeration potential; 2) impurity profile/content; 3) effective density (specific gravity) of the deposited form of the NM; 4) bivariate length and diameter distribution (BVD); 5) surface charge; 6) surface area; 7) rigidity; 8) dustiness; and 9) cellular uptake. While evaluating the MWCNTs at every stage is ideal, it is very resource intensive. Therefore, a list of characteristics should be prioritized to identify the properties of the MWCNTs that are critical to understand the context-specific fate of NMs and their subsequent biological effects. These properties and relevant characterization techniques have been depicted in Fig. 2 and described in the following sections.
Stage1: characterization of MWCNTs as supplied
MWCNTs have diverse physico-chemical properties that are dependent on the procedures used to synthesize them and are relevant to their prospective use. Depending on the synthesis process, MWCNTs can be produced in varying sizes (length and diameter), shapes (straight, rigid, bent, curled, and flexible), and with varying surface chemistry (oxidation status, functionalization, and trace metal content). The diverse physico-chemical properties dictate the lifecycle transformations (e.g., agglomeration, oxidation, and degradation) that MWCNTs will undergo, which eventually translate to different biological and ecological impacts of these MWCNTs.
A number of techniques are available to characterize the pristine form of MWCNTs and have been described in the reports published by the European Commission Joint Research Center (JRC) and the United States National Institute for Occupational Safety and Health (NIOSH) [8, 45]. Table 3 indicates the properties characterized for the pristine form of MWCNTs from various manufacturers and the techniques used, as described in the published literature. Physical dimensions, including length and diameter to estimate aspect ratio, are usually determined using electron microscopy based techniques (SEM and TEM). Specific surface area can be determined using the Brunauer, Emmett and Teller (BET) method; x-ray diffraction can be used to detect the crystal structure; EDS coupled with SEM or TEM can be used to detect the composition of MWCNTs and presence of catalysts; and RAMAN spectroscopy can be used to analyze oxidation status and defects.
Table 3.
MWCNTs type/manufacturer | Characterization | Ref. | |
---|---|---|---|
MWNT-7 (lot #05072001 K28)/Mitsui & Co., Inc. (USA) | MWCNT | [5, 46–50] | |
L (SEM, μm) | 3.86 | ||
D (SEM, nm) | 49 ± 13.4 | ||
Trace metal contamination [sodium (0.41 %) and iron (0.32 %)] (Also reported 1.32 % for total and 1.06 % for iron content) | 0.78 | ||
SSA (BET, m2/g) | 26 | ||
Zeta potential (mV) | -11 | ||
Number of walls | 20–50 | ||
Baytubes/Bayer Material Science, (Germany; no longer commercially available) | MWCNT | [1, 50] | |
Cobalt content (%, wt/wt) (ICP-OES) | 0.46 | ||
Content of cobalt (Co) (%, wt/wt) (AAS) | 0.53 | ||
Elemental analysis (% carbon-oxygen) | 98.6–1.4 | ||
SSA (BET, m2/g) | 253 | ||
Bulk density (g/cm3) | 0.16 | ||
NM400 and NM402/JRC | NM400 | [45, 51, 52] | |
L (SEM, μm) | 0.7–3 | ||
D (SEM, nm) | 5–35 | ||
Impurities total, % Al, % Co | 5.38 total, 0.24, 0.58 | ||
(Also reported 13 % for total impurities) | |||
Defects | 1.2 | ||
SSA (BET, m2/g) | 245.8 | ||
NM401/JRC | CNTLarge | [45, 52] | |
L (SEM, TEM, μm) | 4.05 ± 2.4 | ||
D (SEM, TEM, nm) | 67 ± 26.2 | ||
Impurity (%) | 3 | ||
SSA (BET, m2/g) | 14.6 | ||
NM402/JRC | NM402 | [45, 51] | |
L (SEM, μm) | 0.7–4 | ||
D (SEM, nm) | 6–20 | ||
Impurities total, % Al, % Co | 3.16, | ||
(Also reported 13 % for total impurities) | 3.00 x 10-4, 2.39 | ||
Defects | 1.12 | ||
MWCNTs/Helix Materials Solutions, Inc. (Richardson, TX) | MWCNT | [53–55] | |
L (TEM, μm) | 0.3–50 | ||
D (TEM, nm) | 10–30 | ||
Purity (TGA, %) | >94 | ||
Metal content % Ni, %La (ICP-AES) | 0.34 and 0.03 by weight | ||
Metal %Ni (EDX) | 0.12 | ||
SSA (BET, m2/g) | 109 | ||
Zeta potential (mV) | -13 ± 2 |
Characterization parameters such as length (L), diameter (D), specific surface area (SSA), density, trace metal content, and zeta potential are given for different MWCNTs in addition to the techniques (where available) used for measuring each of the parameters. The techniques used include Brunauer, Emmett and Teller (BET), scanning electron microscopy (SEM), transmission electron microscopy (TEM), inductively coupled plasma atomic emission spectroscopy (ICP-AES), thermogravimetric analysis (TGA), atomic absorption spectroscopy (AAS), and energy-dispersive X-ray spectroscopy (EDX)
Stage 2: administered dose
The administered dose is the MWCNT aerosol atmosphere produced within the exposure chamber at a specific concentration to be tested in the in vitro system. It is analogous to the inhaled dose in an in vivo inhalation exposure study in that it reflects the concentration of the test material and represents the maximal potential dose if all of the test material were deposited. It is important to characterize the administered dose to determine the the physico-chemical composition and form of the test material that is ultimately deposited on cells at the ALI. Chemical properties of the aerosol (e.g., composition, redox potential, and impurities/defects) and the physical features (e.g., particle and mass concentration, settling rates, aerodynamic particle size distribution, and the agglomeration of particles) should be characterized.
Physical features of aerosolized MWCNTs may be measured using a scanning mobility particle spectrometer (SMPS) which includes a differential mobility analyzer (DMA) to determine particle size distribution and a condensation particle counter (CPC) to measure the particle count concentration. An aerodynamic particle sizer (APS) may be used alone or in conjunction with an SMPS to determine aerodynamic properties of the test material. Additionally, a micro-orifice uniform deposit impactor (MOUDI) is used for precise, high accuracy aerosol sampling and for collecting size-fractionated particle samples for gravimetric and/or chemical analysis. The techniques should be chosen based on the NM type; for instance, SMPS might not be appropriate to characterize charged MWCNTs [56]. In addition to aerosol characterization, determination of parameters, such as pressure, temperature, air flow, and relative humidity, inside the exposure-chamber is critical since these parameters can affect the aerosol form that reaches the apical surface of the cells at the ALI.
Stage 3: deposited dose
The deposited dose is the total amount of MWCNTs that deposit on the apical cell layer and is different from the administered dose. Determination of the dose-response relationship requires an accurate measurement of the deposited particle mass onto the cell culture. The most common way to determine the deposited dose is to use the sensor of a QCM [57–59]. The QCM is placed in one empty well of the exposure chamber and exposed to the aerosol. The deposited mass per unit area is monitored as a function of exposure time that is used in calculating the particle concentration. In addition to determining the mass of the deposited MWCNTs, it may be critical to express dose based on the number of particles deposited, as fibers, such as asbestos, are measured in terms of the number of particles per unit volume. The number of fibers deposited can be determined using electron microscopy based methods, where a TEM or SEM grid is placed in the well, and the particles can be counted using representative images of the deposited test material to estimate total particle count. In addition to particle mass and number, surface area is another metric that is considered at the Organisation for Economic Co-operation and Development (OECD) level [60].
Stage 4: cellular dose
The fourth stage of characterization is determining the form and concentration of internalized cellular dose of the MWCNT. The published literature shows that NM cytotoxicity, including MWCNTs, is proportionally related to the dose (or concentration) in terms of mass or particle number, internalized within individual cells, and averaged among the entire cell population. As internalized dose increases, cytotoxicity also increases [61, 62]. Two instruments can be used to determine cellular uptake: TEM is used as a qualitative assessment, while inductively coupled plasma-mass spectroscopy (ICP-MS) is used as a quantitative measure. In the case of MWCNTs, the internalized dose can also be determined directly by elemental carbon analysis or indirectly by measuring the amount of trace metal impurities associated with the MWCNTs using ICP-MS based techniques [63]. Ashing methods have also been developed for measuring the trace metal content, which can then be used to calculate the total dose [64, 65]. In addition to providing some insight into the total dose delivered, determination of trace metal content is an important analytic output since low concentrations of metals may impact the observed toxicological outcome or confound other results [66].
Stage 5: NM transformations
The fifth stage of characterization is measured post-exposure throughout the course of the assay. It is well known that the physico-chemical properties of NMs change when suspended in aqueous media. Particles can undergo changes, such as agglomeration (both homoagglomeration (agglomeration with NMs) and heteroagglomeration (agglomeration with other matrix-specific colloids)), dissolution, and oxidation, as well as changes in surface properties (biodegradation and corona formation). Therefore, collecting aliquots of MWCNTs at different time points in the study is key in evaluating particle transformations [67]. For example, samples should be analyzed using TEM (to record changes in size and/or agglomeration) and ICP-MS (to determine loss of ionic function).
Thorough characterization can help to define parameters specific to MWCNTs for in silico modeling. For instance, the Multi-Path Particle Dosimetry (MPPD) model (available from Applied Research Associates, Inc.) and the In vitro Sedimentation, Diffusion, and Dosimetry (ISDD) model have been used to estimate deposited dose based on particle size for interspecies extrapolation of particle exposures in various species and to understand the kinetics of MWCNTs in the in vitro systems [42, 68, 69]. Such models can be used to make predictions regarding MWCNT fate and transport in complex biological systems that can help in designing in vitro systems that are more predictive of in vivo conditions.
Conclusions
Simulating human-relevant exposure is critical for assessing the toxicological potential of MWCNTs in in vitro systems. When evaluating pulmonary effects (e.g., the development of fibrosis) related to MWCNT exposure for human risk assessment, exposure of relevant cell types (representing the respiratory tract) to aerosolized MWCNTs at the ALI holds greater physiological relevance than traditional submerged cultures. Assessment of inhalation toxicity using cells exposed at the ALI requires an aerosol generator and an exposure chamber. For MWCNTs, all exposure apparatus discussed in this review met the critical needs to establish a robust method, but none address all aspects of an ideal in vitro exposure platform. For example, options not currently included in any model include high throughput capabilities (>10,000 samples per day), available real-time sampling of the basolateral compartment, and generation of fluid shear stress in the basolateral compartment.
The set-up and use of aerosol generation, exposure, and characterization systems requires knowledge about the engineering aspects of aerosol generation and characterization, in addition to the biology of morphologically distinct respiratory tract cells cultured at the ALI. Because of the interdisciplinary nature of the topic, this manuscript fills a critical need of putting forth the parameters that are critical to consider while assessing the inhalation toxicity of MWCNTs using in vitro methods. These parameters include choice of aerosol generation and exposure equipment to study the relevant route and duration of exposure, context-specific characterization of MWCNTs and their transformations at various lifecycle stages, and evaluation of in vitro data in the light of existing information. Although this manuscript focuses on MWCNTs, the technical considerations described here can be applied to the evaluation of inhalation toxicity of other NMs and substances. Development of research strategies based on the parameters evaluated in this manuscript can help in generating comprehensive information on biological endpoints relevant to inhalation exposure to NMs or other larger respirable aerosol particulates, which could be used in the hazard ranking of substances in the risk assessment process.
Acknowledgements
The workshop was funded by the PETA International Science Consortium Ltd., and hosted by the U.S. EPA. ILS staff provided technical support for NICEATM under NIEHS contract HHSN27320140003C and HHSN273201500010C, but do not represent NIEHS, NTP, or the official positions of any Federal agency.
Abbreviations
- AAS
atomic absorption spectroscopy
- Al
aluminum
- ALI
air-liquid interface
- APS
aerodynamic particle sizer
- BET
brunauer, emmett and teller
- BVD
bivariate data
- Co
cobalt
- DLS
dynamic light scattering
- DMA
differential mobility analyzer
- EDX
energy-dispersive X-ray
- EM
electron microscopy
- U. S. EPA
United States environmental protection agency
- GI
gastrointestinal
- ICP-AES
inductively coupled plasma atomic emission spectroscopy
- ICP-MS
inductively coupled plasma mass spectroscopy
- ICP-OES
inductively coupled plasma optical emission spectroscopy
- ILS
integrated laboratory systems, Inc
- ISDD
in vitro sedimentation, diffusion, and dosimetry
- MMAD
mass median aerodynamic diameter
- MPPD
multi-path particle dosimetry
- MOUDI
micro-orifice uniform deposition impactor
- MWCNT
multi-walled carbon nanotube
- NACIVT
nano aerosol chamber for in-vitro toxicity
- NICEATM
NTP interagency center for the evaluation of alternative toxicological methods
- NIEHS
national institute of environmental health science
- NM
nanomaterial
- NTP
national toxicology program
- OC/EC
organic carbon/elemental carbon
- OPPT
office of pollution prevention and toxics
- QCM
quartz crystal microbalance
- RFS
radial flow system
- SEM
scanning electron microscopy
- SMPS
scanning mobility particle sizer spectrometer
- SSA
specific surface area
- TEM
transmission electron microscopy
- TGA
thermogravimetric analysis
- TSCA
toxic substances control act
Footnotes
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
The authors collaboratively prepared the manuscript. WWP and MS focused on exposure systems, CS on aerosol generation and characterization, and JAH on characterization and dosimetry. AJC and MS provided significant input on the overall organization and final review of the manuscript. All authors read and approved the final manuscript.
Contributor Information
William W. Polk, Email: tox.bill@gmail.com
Monita Sharma, Email: MonitaS@piscltd.org.uk.
Christie M. Sayes, Email: csayes@gmail.com
Jon A. Hotchkiss, Email: JAHotchkiss@dow.com
Amy J. Clippinger, Email: AmyJC@piscltd.org.uk
References
- 1.Pauluhn J. Subchronic 13-week inhalation exposure of rats to multiwalled carbon nanotubes: Toxic effects are determined by density of agglomerate structures, not fibrillar structures. Toxicol Sci. 2010;113(1):226–42. doi: 10.1093/toxsci/kfp247. [DOI] [PubMed] [Google Scholar]
- 2.Mercer R.R. et al., Pulmonary fibrotic response to aspiration of multi-walled carbon nanotubes. Part Fibre Toxicol, 2011. 8(21). [DOI] [PMC free article] [PubMed]
- 3.Mercer RR, et al. Alteration of deposition pattern and pulmonary response as a result of improved dispersion of aspirated single-walled carbon nanotubes in a mouse model. Am J Physiol Lung Cell Mol Physiol. 2008;294(1):L87–97. doi: 10.1152/ajplung.00186.2007. [DOI] [PubMed] [Google Scholar]
- 4.Mishra A, et al. Assessment of pulmonary fibrogenic potential of multiwalled carbon nanotubes in human lung cells. J Nanomater. 2012;2012:11. [Google Scholar]
- 5.Porter DW, et al. Mouse pulmonary dose- and time course-responses induced by exposure to multiwalled carbon nanotubes. Toxicology. 2010;269(2):136–47. doi: 10.1016/j.tox.2009.10.017. [DOI] [PubMed] [Google Scholar]
- 6.Umeda Y, et al. Two-week Toxicity of Multi-walled Carbon Nanotubes by Whole-body Inhalation Exposure in Rats. J Toxicol Pathol. 2013;26(2):131–40. doi: 10.1293/tox.26.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Kasai T, et al. Thirteen-week study of toxicity of fiber-like multi-walled carbon nanotubes with wholebody inhalation exposure in rats. Nanotoxicology. 2015;9(4):413–22. doi: 10.3109/17435390.2014.933903. [DOI] [PubMed] [Google Scholar]
- 8.NIOSH, Current Intelligence Bulletin 65: Occupational exposure to carbon nanotubes and nanofibers. Online at: http://www.cdc.gov/niosh/docs/2013-145/pdfs/2013-145.pdf, 2013.
- 9.Siebert TA, Rugonyi S. Influence of liquid-layer thickness on pulmonary surfactant spreading and collapse. Biophys J. 2008;95(10):4549–59. doi: 10.1529/biophysj.107.127654. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Kleinstreuer C, Zhang Z, Donohue JF. Targeted drug-aerosol delivery in the human respiratory system. Annu Rev Biomed Eng. 2008;10:195–220. doi: 10.1146/annurev.bioeng.10.061807.160544. [DOI] [PubMed] [Google Scholar]
- 11.Yacobi NR, et al. Nanomaterial interactions with and trafficking across the lung alveolar epithelial barrier: implications for health effects of air-pollution particles. Air Qual Atmos Health. 2011;4(1):65–78. doi: 10.1007/s11869-010-0098-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Politis M, Pilinis C, Lekkas TD. Ultrafine particles (UFP) and health effects. Dangerous. Like no other PM? Global Nest. 2008;10:439–52. [Google Scholar]
- 13.Frohlich E, Salar-Behzadi S. Toxicological assessment of inhaled nanoparticles: role of in vivo, ex vivo, in vitro, and in silico studies. Int J Mol Sci. 2014;15(3):4795–822. doi: 10.3390/ijms15034795. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Wetsel RA, Wang D, Calame DG. Therapeutic potential of lung epithelial progenitor cells derived from embryonic and induced pluripotent stem cells. Annu Rev Med. 2011;62:95–105. doi: 10.1146/annurev-med-052009-172110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Fronius M, Clauss WG, Althaus M. Why do we have to move fluid to be able to breathe? Front Physiol. 2012;3:146. doi: 10.3389/fphys.2012.00146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Geiser M. and Kreyling WG. Deposition and biokinetics of inhaled nanoparticles. Particle and Fibre Toxicology, 2010. 7(2). [DOI] [PMC free article] [PubMed]
- 17.Gehr P, Bachofen M, Weibel ER. The normal human lung: ultrastructure and morphometric estimation of diffusion capacity. Respir Physiol. 1978;32(2):121–40. doi: 10.1016/0034-5687(78)90104-4. [DOI] [PubMed] [Google Scholar]
- 18.Paur H-R, et al. In-vitro cell exposure studies for the assessment of nanoparticle toxicity in the lung—A dialog between aerosol science and biology. J Aerosol Sci. 2011;42(10):668–92. doi: 10.1016/j.jaerosci.2011.06.005. [DOI] [Google Scholar]
- 19.Jiménez AS, Brouwer D, Tongeren MV. Workplace inhalation exposure to engineered nanomaterials, in Nanotoxicology. Boca Raton: CRC Press; 2014. pp. 77–96. [Google Scholar]
- 20.Hayes A, Bakand S, Winder C. Novel in-vitro exposure techniques for toxicity testing and biomonitoring of airborne contaminants, in Drug Testing in vitro. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2006. pp. 103–23. [Google Scholar]
- 21.Sayes CM, Reed KL, Warheit DB. Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. Toxicol Sci. 2007;97(1):163–80. doi: 10.1093/toxsci/kfm018. [DOI] [PubMed] [Google Scholar]
- 22.Cho SH, et al. Comparative toxicity of size-fractionated airborne particulate matter collected at different distances from an urban highway. Environ Health Perspect. 2009;117(11):1682–9. doi: 10.1289/ehp.0900730. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Yamaguchi T, Yamazaki H. Cytotoxicity of airborne particulates sampled roadside in rodent and human lung fibroblasts. Journal of health science. 2001;47(3):272–77. doi: 10.1248/jhs.47.272. [DOI] [Google Scholar]
- 24.Morin JP, et al. Development of a new in vitro system for continuous in vitro exposure of lung tissue to complex atmospheres: application to diesel exhaust toxicology. Cell Biol Toxicol. 1999;15(3):143–52. doi: 10.1023/A:1007625302215. [DOI] [PubMed] [Google Scholar]
- 25.NRC, Toxicity Testing in the 21st Century: A Vision and a Strategy2007, Washington, DC: The National Academies Press. 216
- 26.Brandenberger C, et al. Effects and uptake of gold nanoparticles deposited at the air–liquid interface of a human epithelial airway model. Toxicol Appl Pharmacol. 2010;242(1):56–65. doi: 10.1016/j.taap.2009.09.014. [DOI] [PubMed] [Google Scholar]
- 27.Oberdorster G, et al. Inhalation Exposure to Carbon Nanotubes (CNT) and Carbon Nanofibers (CNF): Methodology and Dosimetry. J Toxicol Environ Health B Crit Rev. 2015;18(3–4):121–212. doi: 10.1080/10937404.2015.1051611. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Lenz A.G. et al. A dose-controlled system for air-liquid interface cell exposure and application to zinc oxide nanoparticles. Part Fibre Toxicol, 2009. 6(32). [DOI] [PMC free article] [PubMed]
- 29.Persoz C, et al. Sequential air-liquid exposure of human respiratory cells to chemical and biological pollutants. Toxicol Lett. 2011;207(1):53–9. doi: 10.1016/j.toxlet.2011.07.028. [DOI] [PubMed] [Google Scholar]
- 30.Frohlich E, et al. Comparison of two in vitro systems to assess cellular effects of nanoparticles containing aerosols. Toxicol In Vitro. 2013;27(1):409–17. doi: 10.1016/j.tiv.2012.08.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Nurkiewicz T.R. et al. Nanoparticle inhalation augments particle-dependent systemic microvascular dysfunction. Part Fibre Toxicol, 2008. 5(1). [DOI] [PMC free article] [PubMed]
- 32.Oberdorster G. Lung Clearance of Inhaled Insoluble and Soluble Particles. J Aerosol Med. 1988;1(4):289–330. doi: 10.1089/jam.1988.1.289. [DOI] [Google Scholar]
- 33.Brown J.S. et al. Thoracic and respirable particle definitions for human health risk assessment. Particle and Fibre Toxicology, 2013. 10(12). [DOI] [PMC free article] [PubMed]
- 34.Dailey LA, et al. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Control Release. 2003;86(1):131–44. doi: 10.1016/S0168-3659(02)00370-X. [DOI] [PubMed] [Google Scholar]
- 35.Kim SC, et al. A nanoparticle dispersion method for in vitro and in vivo nanotoxicity study. Nanotoxicology. 2010;4(1):42–51. doi: 10.3109/17435390903374019. [DOI] [PubMed] [Google Scholar]
- 36.Baron PA, et al. Development of an aerosol system for uniformly depositing Bacillus Anthracis spore particles on surfaces. Aerosol Sci Technol. 2008;42(3):159–72. doi: 10.1080/02786820801918605. [DOI] [Google Scholar]
- 37.Baron PA, et al. Aerosolization of single-walled carbon nanotubes for an inhalation study. Inhal Toxicol. 2008;20(8):751–60. doi: 10.1080/08958370801975303. [DOI] [PubMed] [Google Scholar]
- 38.Mitchell LA, et al. Pulmonary and systemic immune response to inhaled multiwalled carbon nanotubes. Toxicol Sci. 2007;100(1):203–14. doi: 10.1093/toxsci/kfm196. [DOI] [PubMed] [Google Scholar]
- 39.Soni P.S.a. and B. Raghunath. Generation of aerosols: BARC nebulizer and others, in Radioaerosol imaging of Ihe lung, I.T. Bahk YW, Editor 1994, International Atomic Energy Agency Publication: Vienna. p. 24–42.
- 40.Kasai T, et al. Development of a new multi-walled carbon nanotube (MWCNT) aerosol generation and exposure system and confirmation of suitability for conducting a single-exposure inhalation study of MWCNT in rats. Nanotoxicology. 2014;8(2):169–78. doi: 10.3109/17435390.2013.766277. [DOI] [PubMed] [Google Scholar]
- 41.Taquahashi Y, et al. Improved dispersion method of multi-wall carbon nanotube for inhalation toxicity studies of experimental animals. J Toxicol Sci. 2013;38(4):619–28. doi: 10.2131/jts.38.619. [DOI] [PubMed] [Google Scholar]
- 42.Hinderliter PM, et al. ISDD: A computational model of particle sedimentation, diffusion and target cell dosimetry for in vitro toxicity studies. Part Fibre Toxicol. 2010;7(1):36. doi: 10.1186/1743-8977-7-36. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Warheit DB, et al. Pulmonary toxicity study in rats with three forms of ultrafine-TiO2 particles: differential responses related to surface properties. Toxicology. 2007;230(1):90–104. doi: 10.1016/j.tox.2006.11.002. [DOI] [PubMed] [Google Scholar]
- 44.Ekstrand-Hammarstrom B, et al. Human primary bronchial epithelial cells respond differently to titanium dioxide nanoparticles than the lung epithelial cell lines A549 and BEAS-2B. Nanotoxicology. 2012;6(6):623–34. doi: 10.3109/17435390.2011.598245. [DOI] [PubMed] [Google Scholar]
- 45.JRC, Multi-walled carbon nanotubes, NM-400, NM-401, NM-402, NM-403: Characterisation and physico-chemical properties. Online at: http://publications.jrc.ec.europa.eu/repository/bitstream/JRC91205/mwcnt-online.pdf, 2014.
- 46.Takagi A, et al. Induction of mesothelioma in p53+/− mouse by intraperitoneal application of multi-wall carbon nanotube. J Toxicological Sci. 2008;33(1):105–16. doi: 10.2131/jts.33.105. [DOI] [PubMed] [Google Scholar]
- 47.Poland CA, et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nano. 2008;3(7):423–28. doi: 10.1038/nnano.2008.111. [DOI] [PubMed] [Google Scholar]
- 48.Mercer R.R. et al. Distribution and fibrotic response following inhalation exposure to multi-walled carbon nanotubes. Part Fibre Toxicol, 2013. 10(33). [DOI] [PMC free article] [PubMed]
- 49.Sos Poulsen S, et al. Transcriptomic analysis reveals novel mechanistic insight into murine biological responses to multi-walled carbon nanotubes in lungs and cultured lung epithelial cells. PLoS ONE. 2013;8(11) doi: 10.1371/journal.pone.0080452. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.FIOH, Evaluation of the health effects of carbon nanotubes. Online at: http://www.tsr.fi/c/document_library/get_file?folderId=13109&name=DLFE-9367.pdf, 2013.
- 51.Vietti G. et al. Towards predicting the lung fibrogenic activity of nanomaterials: experimental validation of an in vitro fibroblast proliferation assay. Part Fibre Toxicol, 2013. 10(52). [DOI] [PMC free article] [PubMed]
- 52.Poulsen SS, et al. MWCNTs of different physicochemical properties cause similar inflammatory responses, but differences in transcriptional and histological markers of fibrosis in mouse lungs. Toxicol Appl Pharmacol. 2015;284(1):16–32. doi: 10.1016/j.taap.2014.12.011. [DOI] [PubMed] [Google Scholar]
- 53.Cesta MF, et al. Bacterial lipopolysaccharide enhances PDGF signaling and pulmonary fibrosis in rats exposed to carbon nanotubes. Am J Respir Cell Mol Biol. 2010;43(2):142–51. doi: 10.1165/rcmb.2009-0113OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Taylor AJ, et al. Atomic layer deposition coating of carbon nanotubes with aluminum oxide alters profibrogenic cytokine expression by human mononuclear phagocytes in vitro and reduces lung fibrosis in mice in vivo. PLoS One. 2014;9(9) doi: 10.1371/journal.pone.0106870. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Hussain S. et al. Inflammasome activation in airway epithelial cells after multi-walled carbon nanotube exposure mediates a profibrotic response in lung fibroblasts. Part Fibre Toxicol, 2014. 11(28). [DOI] [PMC free article] [PubMed]
- 56.Ku BK, et al. Observation and measurement of anomalous responses in a differential mobility analyzer caused by ultrafine fibrous carbon aerosols. Journal of Electrostatics. 2007;65(8):542–48. doi: 10.1016/j.elstat.2006.10.012. [DOI] [Google Scholar]
- 57.Burg TP, et al. Weighing of biomolecules, single cells and single nanoparticles in fluid. Nature. 2007;446(7139):1066–9. doi: 10.1038/nature05741. [DOI] [PubMed] [Google Scholar]
- 58.Lenz AG, et al. A dose-controlled system for air-liquid interface cell exposure and application to zinc oxide nanoparticles. Part Fibre Toxicol. 2009;6(1):1–17. doi: 10.1186/1743-8977-6-32. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Endes C, et al. An in vitro testing strategy towards mimicking the inhalation of high aspect ratio nanoparticles. Part Fibre Toxicol. 2014;11(1):1–13. doi: 10.1186/s12989-014-0040-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.OECD, Guidance on sample preparation and dosimetry for the safety testing of manufactured nanomaterials. Series on the Safety of Manufactured Nanomaterials No. 36. Online at: http://search.oecd.org/officialdocuments/displaydocumentpdf/? cote=env/jm/mono(2012)40&doclanguage=en, 2012.
- 61.Magrez A, et al. Cellular toxicity of carbon-based nanomaterials. Nano Lett. 2006;6(6):1121–5. doi: 10.1021/nl060162e. [DOI] [PubMed] [Google Scholar]
- 62.Hussain SM, et al. In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol In Vitro. 2005;19(7):975–83. doi: 10.1016/j.tiv.2005.06.034. [DOI] [PubMed] [Google Scholar]
- 63.Erdely A. et al. Carbon nanotube dosimetry: from workplace exposure assessment to inhalation toxicology. Particle and Fibre Toxicology, 2013. 10(53). [DOI] [PMC free article] [PubMed]
- 64.Ge C, et al. Quantitative analysis of metal impurities in carbon nanotubes: Efficacy of different pretreatment protocols for ICPMS spectroscopy. Analytical Chemistry. 2008;80(24):9426–34. doi: 10.1021/ac801469b. [DOI] [PubMed] [Google Scholar]
- 65.Mortari SR, et al. Fast digestion procedure for determination of catalyst residues in La- and Ni-based carbon nanotubes. Analytical Chemistry. 2010;82(10):4298–303. doi: 10.1021/ac100429v. [DOI] [PubMed] [Google Scholar]
- 66.Bonner JC, et al. Interlaboratory evaluation of rodent pulmonary responses to engineered nanomaterials: the NIEHS Nano GO Consortium. Environ Health Perspect. 2013;121(6):676–82. doi: 10.1289/ehp.1205693. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Berg JM, et al. The relationship between pH and zeta potential of ∼ 30 nm metal oxide nanoparticle suspensions relevant to in vitro toxicological evaluations. Nanotoxicology. 2009;3(4):276–83. doi: 10.3109/17435390903276941. [DOI] [Google Scholar]
- 68.Anjilvel S, Asgharian B. A multiple-path model of particle deposition in the rat lung. Fundam Appl Toxicol. 1995;28(1):41–50. doi: 10.1006/faat.1995.1144. [DOI] [PubMed] [Google Scholar]
- 69.RIVM, Multiple Path Particle Dosimetry Model (MPPD v 1.0): A Model for Human and Rat Airway Particle Dosimetry. Model available online at: http://www.ara.com/products/mppd.htm, 2002, National Institute for Public Health and the Environment Bilthoven, Netherlands